Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Saturday, 05 / 30 / 2020

Articles

COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies

REVIEW ARTICLE

COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies

Gong Feng#,1, Kenneth I. Zheng#,2, Qin-Qin Yan1, Rafael S. Riosn2, Giovanni Targher3, Christopher D. Byrne4, Sven Van Poucke5, Wen-Yue Liu6 and Ming-Hua Zheng*,2,7,8

Xi’an Medical University, Xi’an, China
NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy
Southampton National Institute for Health Research Biomedical Research Center, University Hospital Southampton, Southampton General Hospital, Southampton, UK
Ziekenhuis Oost-Limburg, Department of Anesthesiology, Critical Care, Emergency Medicine and Pain Therapy, Genk, Belgium
Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
Institute of Hepatology, Wenzhou Medical University, Wenzhou, China
Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China

*Correspondence to: Ming-Hua Zheng, NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou 325000, China. Tel: +86-577-55579622, Fax: +86-577-55578522E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2020;8(1):18-24 DOI: 10.14218/JCTH.2020.00018
Received: March 8, 2020 Accepted: March 17, 2020 Published online: March 30, 2020

Abstract

The outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has attracted increasing worldwide attention. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19-related liver damage/dysfunction is due mainly to the viral infection per se or other coexisting conditions, such as the use of potentially hepatotoxic drugs and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Based on the current evidence from case reports and case series, this review article focuses on the demographic and clinical characteristics, potential mechanisms, and treatment options for COVID-19-related liver dysfunction. This review also describes the geographical and demographic distribution of COVID-19-related liver dysfunction, as well as possible underlying mechanisms linking COVID-19 to liver dysfunction, in order to facilitate future drug development, prevention, and control measures for COVID-19.

Keywords

COVID-19, Liver dysfunction, SARS-CoV-2

Journal of Clinical and Translational Hepatology 2020 vol. 8, 18-24  [ Html ] [ PDF Full-text ]

© The Authors 2020. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

 logo

You are here: Home